The purpose of this research is to determine if cagrilintide is more effective than placebo in helping people lose weight. The study will specifically look at whether the medication can help people achieve a reduction of at least 5% of their body weight. During the study, participants will receive either cagrilintide or placebo injections for approximately 64 weeks.

The study will measure various health indicators including changes in body weight, waist size, blood pressure, and different types of cholesterol in the blood. It will also assess how the treatment affects quality of life and overall health. Throughout the study, participants’ safety will be monitored by tracking any side effects that may occur.

The purpose of the study is to determine whether dosing guided by AUC leads to a higher proportion of participants reaching the desired drug level eight weeks after the transplant compared with standard dosing. AUC (area under the curve) is a measurement that reflects how much drug is present in the blood over a set time period. Participants will have blood samples taken at several points after the transplant, and the dose of tacrolimus will be adjusted based on these results. The study follows participants for a few months, with regular visits to collect samples and check safety.

Participants are randomly assigned to receive either belumosudil tablets taken by mouth or one of the comparator medicines chosen by their doctor. The study lasts about 24 weeks, during which regular clinic visits are scheduled to check symptoms, perform blood tests, and assess overall health. Researchers look at the overall response rate, which means the percentage of people whose disease shows improvement, using standard doctor‑approved guidelines (NIH consensus response criteria). Systemic therapy refers to medicines that work throughout the whole body, and any need for new systemic treatment, relapse of the underlying disease, or death is recorded.

Throughout the trial, safety is closely monitored; blood samples are taken to measure drug levels and to watch for side effects. Participants can stop the study at any time if they experience problems. The information gathered will help determine whether belumosudil works better and is safe for people with this condition.

The goal of the research is to find out whether a lower dose of the drug works just as well as the standard full dose for these patients. Participants are randomly assigned to receive either the reduced dose or the full dose, and they are monitored closely for about a week to see how they respond, including any need for life‑support measures or repeat clot events.

During the study, doctors watch for signs of improvement such as stable blood pressure, better oxygen levels, and the ability to breathe without extra machines. They also keep track of any serious bleeding problems. The overall plan is to compare the two dosing strategies to see if the lower amount can provide the same benefit with potentially fewer side effects.

The purpose of the study is to see if GSK6042981 works better than sunitinib malate in slowing down the growth of the cancer or stopping it from getting worse. Patients taking part in this study will be randomly assigned to receive either GSK6042981 or sunitinib malate, and both groups will know which medicine they are receiving. During the study, doctors will monitor how well the treatment is working and how long patients can go without their disease getting worse. Patients will also be asked about their quality of life and any side effects they may experience.

Throughout the study, doctors will collect tissue samples from tumors for laboratory testing, which may come from previously stored tissue or from a new biopsy. The study will also measure the levels of GSK6042981 in the blood and track various aspects of patient health, including how long patients live, how quickly the tumor responds to treatment, and whether the cancer gets worse after starting a different treatment following the study medicine. Patients will complete questionnaires about their symptoms and overall well-being to help researchers understand how the treatments affect daily life.

The purpose of the trial is to determine whether the new medicine works as well as, or better than, the standard treatment in patients who have not received prior therapy for this condition. This phase 3 investigation uses a randomized, open-label design, meaning participants are assigned by chance to one of the two drugs and both the study team and participants know which drug is being taken. After enrollment, participants receive daily medication and attend regular clinic visits for safety checks and imaging scans that monitor the tumor. The study follows each person until the cancer shows signs of worsening, which is measured as progression-free survival, or until side effects require stopping the medication.

The purpose is to see how each regimen changes the heart’s electrical timing, measured as the QTc interval on a standard ECG. Participants will receive each hormone regimen for about four weeks in a random order, with a short break between periods. During each period, a tiny implanted device (ILR) records any serious heart rhythm problems, and regular check‑ups track symptoms and hormone effects. After the short treatment phases, participants are observed for a longer time while continuing usual care.

The purpose of the study is to compare how well the new oral tablet, alone or combined with standard chemotherapy, works against standard chemotherapy alone in controlling the cancer. Participants are randomly assigned to one of the three groups and receive treatment in repeating 28‑day cycles. During the study, regular doctor visits, imaging scans, blood tests, and quality‑of‑life questionnaires are performed to track disease status and any side effects. Treatment continues until the cancer grows, side effects become unacceptable, or the study ends after about two years.

Randomly assigned means the chance decides which group a participant joins, helping to keep the comparison fair. Open‑label indicates that both the medical team and participants know which treatment is being given. A cycle refers to a set period of treatment followed by a short rest, typically one month. Progression means the cancer is getting larger or spreading, which doctors watch for using standard imaging methods.

The purpose of the trial is to determine whether this combination can achieve durable immunological control of the virus when antiretroviral therapy is stopped. After receiving the study infusions, participants will pause their regular ART under close medical supervision and will have regular blood tests to monitor viral levels and immune‑cell counts; if the virus rises above predefined thresholds or immune cells fall, treatment will be restarted.

During the entire study period, participants will be monitored for any side effects or laboratory changes, and any serious problems will be reported to the study team, with follow‑up extending for several months after the therapy interruption.

After the gadobutrol injection, blood samples will be taken at several time points to see how the substance moves through the body, and the children will continue their regular chemotherapy schedule. Participants will be observed for any immediate reactions for about half an hour after the injection and will be asked about common symptoms such as headache, nausea, or dizziness during the first week. Additional follow‑up visits will include simple questionnaires that measure mental fatigue and more detailed tests of thinking and memory at three months, and again at two years, to check for any changes in brain function. All procedures are designed to be as safe and comfortable as possible while gathering information that could help tailor future treatments.

The purpose of the study is to see whether adding Rinatabart Sesutecan can keep the cancer from growing for a longer time compared with the usual treatment alone. Participants are randomly placed into one of the two groups after completing their second‑line chemotherapy, then they receive the assigned maintenance therapy for several months while doctors monitor their health through regular clinic visits and scans.

Progression‑free survival means the period during which the cancer does not get worse. Doctors use a set of rules called RECIST to measure whether tumors have grown or shrunk on imaging tests. To understand how the treatments affect overall well‑being, participants also complete a questionnaire known as the EORTC QLQ‑C30, which asks about symptoms, daily activities, and overall quality of life.

The purpose of the study is to determine whether reducing or stopping the medication after the disease has been quiet for at least a year changes the chance of a worsening episode compared with continuing the same dose.

Participants who meet the criteria will be randomly assigned to either keep the same amount of medicine (stable dose) or to slowly lower the amount and eventually stop (tapered). Over the following 12 months they will attend regular check‑ups where doctors will look for signs of a flare, which means a noticeable increase in joint pain, swelling or loss of movement, indicating the disease is no longer in an inactive disease state. If a flare occurs, treatment can be restarted to bring the condition back under control, and safety and any side effects are recorded throughout the year.

The purpose of the study is to find out whether giving Salanersen about six months after the gene‑therapy is safe and can be tolerated well. Children who take part will receive the injection and then be seen regularly for several years. At each visit they will have simple blood draws and brief examinations to check how they are doing.

During the study doctors will watch for any side effects and will also look at a protein called neurofilament light chain that can show nerve damage, and they will perform a test called compound muscle action potential that measures how nerves and muscles work together. The children’s ability to reach basic movement goals such as sitting, standing and walking will be recorded using the World Health Organization motor milestones and other easy‑to‑understand scales like the Hammersmith Infant Neurological Examination, CHOP INTEND, Hammersmith Functional Motor Scale Expanded and Revised Upper Limb Module. The follow‑up continues until the children are several years old, allowing researchers to see long‑term safety and any signs of benefit.

The purpose is to compare how well the cancer is controlled when the experimental drug is added to chemotherapy versus chemotherapy alone. After enrollment, participants are randomly assigned to one of the two groups, take the study medication daily in tablet form, and undergo regular clinic visits for treatment cycles and safety checks. The study continues until the disease progresses, the participant stops treatment, or the study ends, with follow‑up visits to monitor overall health and any side effects.

Participants will receive a series of scheduled treatment visits where the assigned medication is administered, followed by regular check‑ups that include blood tests and other simple exams to monitor the disease and any side effects. The study lasts for several years, with visits occurring at set intervals, and ends when the participant stops the medication or the study concludes.

The purpose of the study is to see how well Concizumab works in preventing bleeding episodes compared to the previous treatment the children were receiving. The study will involve children who have not used Concizumab before. Participants will receive regular injections of Concizumab over a period of time, and the number of bleeding episodes they experience will be monitored and compared to their previous treatment.

Throughout the study, researchers will also keep track of any side effects or reactions to the medication, such as injection site reactions or the development of antibodies against Concizumab. The study aims to provide valuable information on the safety and effectiveness of Concizumab in managing bleeding episodes in young children with hemophilia.

The purpose of the study is to see whether a higher radiation dose improves overall survival. Participants will be randomly assigned to receive either the standard radiation dose or a higher dose, then all will continue with the same durvalumab treatment. The study follows patients for several months, checking how long they live, how the cancer responds, any side effects, and how they feel in daily life.

The purpose of the study is to find out whether JNJ-78934804 can bring participants to a state of clinical remission (no noticeable symptoms) and an endoscopic remission (no visible inflammation when doctors look inside the gut with a camera) by week 48. Participants will receive a series of injections over about a year and will attend regular clinic visits where doctors check health, assess symptoms and may perform simple imaging to look at the gut. Throughout the study, neither the participants nor the treating doctors know which medication is being given, helping to keep the results unbiased.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

The purpose of the study is to determine whether nerandomilast can more effectively delay death or disease worsening compared with the placebo.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year. During this time, they will attend regular clinic visits where doctors will check skin thickness, lung function (including a test called FVC that measures how much air can be forced out of the lungs), physical ability, and overall health. The study will track any serious health events, changes in symptoms, and overall survival throughout the treatment period.

The purpose of the study is to identify the optimal amount of the medication and to evaluate its ability to shrink or stop the growth of the cancer (anti‑tumour activity). The research is conducted as a phase II trial, meaning it is designed to test different dose levels for safety and effectiveness after initial safety has been shown.

Participants receive a series of injections of the study drug into the tumor at scheduled visits, followed by regular medical examinations, imaging scans, and questionnaires that assess symptoms and overall well‑being. The study continues until the treatment plan is completed or until the disease progresses, with ongoing monitoring to record any side effects and changes in the tumor size.

The purpose of the study is to find out which of these treatments best prevents death, heart attack (also called myocardial infarction) or stroke during the first year after the heart event while also keeping serious bleeding low. Participants will take the assigned tablet once daily for up to 12 months and will attend scheduled visits to monitor their health.

During the year, participants will have regular visits where doctors check health, ask about any new problems, and record any occurrences of heart attack, stroke, death, or major bleeding. This information is used to compare the safety and effectiveness of the medicines.

The purpose of the study is to assess how safe the new injection is and how it changes the activity of a clotting protein called factor XI (FXI) over a 16‑week period. Participants will be randomly assigned to receive one of two hidden doses of the injection or the placebo, and all will receive the open‑label tablet. Visits will include simple blood draws to measure FXI activity and routine safety checks such as checking for bleeding or other side effects.

Throughout the trial, researchers will watch for any bleeding events, record any adverse experiences, and perform standard laboratory tests and vital‑sign measurements. Blood samples will also be taken at several time points to see how the drug behaves in the body and whether the immune system produces any antibodies against it.

The purpose of the study is to determine whether ALKS 2680 can reduce daytime sleepiness in adults with Narcolepsy Type 1. Participants will be randomly assigned to receive either the study drug or a placebo for about twelve weeks. During the study, they will complete a questionnaire called the Epworth Sleepiness Scale that asks how likely they are to fall asleep in everyday situations, and they will take a short test called the Maintenance of Wakefulness Test that measures how long they can stay awake when asked to do so. Their episodes of cataplexy will also be recorded each week.

Throughout the trial, researchers will monitor participants for any side effects and will collect the questionnaire and test results to evaluate the safety and effectiveness of the medication. The collected information will help decide if the drug provides a beneficial option for managing the symptoms of this sleep disorder.

The main aim of the study is to evaluate how often the tumors shrink, known as an objective response. Participants receive the study drug in treatment cycles that repeat every few weeks, with regular visits for physical exams, blood tests, and imaging scans to check the size of the tumor and overall health.

Tumor shrinkage is classified as a complete response when the cancer disappears, a partial response when the tumor size decreases by a significant amount, or stable disease when the tumor does not grow or shrink much. Throughout the trial, doctors monitor for adverse events, which are side effects or any unwanted medical problems, and record any that are serious or lead to stopping the treatment.

Participants will receive a series of injections of either the study drug or the placebo over several months, with regular clinic visits for safety checks and simple breathing tests. One key breathing test measures the amount of air expelled in the first second of a forced breath, known as Forced Expiratory Volume in 1 second, to see how lung function changes. Throughout the study, people will complete questionnaires that assess health status and symptoms, such as the SGRQ-C (a quality‑of‑life survey), the CAAT (a symptom score), and the E-RS:COPD diary (records daily breathing problems). Researchers will also monitor for any side effects, using terms like TEAEs (any undesirable effects), AESIs (specific safety concerns), and SAEs (serious problems). Blood samples will be taken to check the drug level and to look for antidrug antibodies, which are the body’s immune response to the medication.

The purpose of the trial is to determine whether this combined therapy is safe and practical for this age group. Participants first undergo screening and baseline assessments, then attend a series of therapy sessions during which the medication is taken in capsule form. After the treatment phase, they continue with follow‑up visits to monitor any side effects and to observe changes in mood and daily functioning, while a separate group receives the same therapy at a later time for comparison.

The purpose of the study is to determine whether this therapy improves heart performance and is safe compared with standard care. Participants are randomly assigned to receive either the insulin‑based regimen plus usual treatment or usual treatment alone. The study treatment is given for up to two days while patients remain in the hospital, during which doctors watch heart function, blood pressure, kidney function and any side effects using a thin tube called a catheter (via pulmonary artery catheterization) and regular blood tests. After leaving the hospital, patients are checked again for about six weeks to see if they needed extra heart‑support devices and how well the heart and kidneys are working.

Safety monitoring includes continuous observation of heart rhythm, blood pressure, and the amounts of other heart‑support medicines used. The trial is open label, meaning both the care team and the participants know which treatment is being given, and it is designed as a small pilot to gather early information about the new approach.

The purpose of the study is to evaluate whether Orelabrutinib can delay the worsening of disability compared with placebo. Participants will receive the assigned tablet each day for several years and will attend regular clinic visits where their ability to perform everyday tasks is checked and brain scans using MRI are performed to look for new lesions. The study will track how long it takes before a confirmed increase in disability occurs and will record any safety concerns throughout the trial.

The aim is to find out whether the nasal dose of the study drug reduces the pain measured by the Premature Infant Pain Profile‑Revised during the first 30 seconds after the eye speculum is placed. Infants are randomly assigned to receive either the study drug or the placebo, then undergo the standard eye screening while pain scores and basic vital signs are recorded. After the exam the infants continue to be observed for a short period to monitor any breathing changes, oxygen needs, crying, sleep, or other reactions before returning to regular care.

The purpose of the study is to assess the long‑term safety and clinical benefit of the medication. Participants will take the granules by mouth each day for an extended period and will attend regular visits where doctors will check how they are feeling and perform simple tests.

During the visits, several simple assessments are done: a muscle‑function questionnaire called NSAD, a walking speed test over ten meters known as the 10MWT, a breathing test that measures how much air can be exhaled called FVC, an upper‑limb function test named PUL 2.0, a walking distance test over one hundred meters called 100MTT, and a blood test that measures a protein called CK which indicates muscle damage. These checks help researchers understand how the medication affects muscle strength, movement, and overall health over time.

The purpose of this phase II study is to find out whether taking sirolimus after surgery can lead to a lasting reduction in the size of the affected lip and a change in the color of the birthmark, while also checking safety and how the condition impacts quality of life. Participants will start the medication after their surgical procedure and will be followed for several years, with periodic visits to measure the lip’s size with a simple ruler, to assess color changes using a four‑step scale, and to complete questionnaires that ask about daily activities and comfort.